Literature DB >> 7229376

Immunologic control of the ascites form of murine adenocarcinoma 755. III. Efficacy of serum therapy is controlled by a single genetic locus.

G J Roloson, D E Haagensen, C A Chambers, D P Bolognesi.   

Abstract

We have previously described a passive serum therapy system in which potent protection against challenge of syngeneic mice with large doses (10(4) X LD100) of AD755a tumor cells can be accomplished by administration of as little as 2 to 5 microliters/mouse of hyperimmune anti-tumor cell serum. The present results demonstrate that the efficacy of the serum protection effect is strain-dependent and is under the control of a single genetic locus, denoted ADP-1. Through a series of crosses between highly protected C57BL/6J and nonprotected BALB/cJ mice, the ADP-locus has been mapped to chromosome 2 [linkage group V], approximately 23 centimorgans toward te centromere from the locus controlling agouti coat color. Thus, the protection locus is not linked to either the H-2 region or to previously described loci regulating the replication and disease induction of type-C viruses closely related to the virus associated with the AD775a tumor. The possible functions of the ADP-1 locus are discussed and further aspects of this experimental model are described in the accompanying papers.

Entities:  

Mesh:

Year:  1981        PMID: 7229376

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  The SMXA: a new set of recombinant inbred strain of mice consisting of 26 substrains and their genetic profile.

Authors:  M Nishimura; N Hirayama; T Serikawa; K Kanehira; Y Matsushima; H Katoh; S Wakana; A Kojima; H Hiai
Journal:  Mamm Genome       Date:  1995-12       Impact factor: 2.957

2.  Non-human primate (baboon) anti-gross cystic disease fluid protein-15 antibody infusion in four women with metastatic breast carcinoma.

Authors:  A Estabrook; S J Kister; M A Hardy; L Grossbard; M W Oster; S Davis; G Mazoujian; D E Haagensen
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen.

Authors:  C C Badger; I D Bernstein
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.